SHR-2017

Unknown / undisclosed

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Bone Metastases from Solid Tumors
NCT07028268 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-06-24 – 2027-05 · For Prevention of Bone Events in Patients With Bone Metastases From Solid Tumors
What this study did
Phase 1 (2)
Other / comorbidity
NCT06380881 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2024-05-20 – 2025-08-06 · Patients With Bone Metastases
What this study did
NCT05930704 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2023-07-04 – 2025-04-12 · Osteoporosis
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

No upcoming readouts on record for this asset.